Alfresa Holdings Corporation

Equities

2784

JP3126340003

Medical Equipment, Supplies & Distribution

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,295 ^JPY	+4.20%		+6.84%	-4.24%

Feb. 08	Alfresa Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI
Feb. 08	Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2024	CI

Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

February 08, 2024 at 01:30 am EST

Alfresa Holdings Corporation provided consolidated earnings guidance for the full year ending March 31, 2024. For the year, the company expects net sales to be JPY 2,860,000 million, operating income to be JPY 36,000 million, profit attributable to owners of the parent to be JPY 24,900 million and basic earnings per share to be JPY 129.87.

Latest news about Alfresa Holdings Corporation

Alfresa Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024	Feb. 08	CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the First Half Ended September 30, 2023 and Fiscal Year March 31, 2024	23-10-31	CI
Alfresa Holdings Completes 35 Billion Yen Share Buyback program	23-10-03	MT
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	23-10-03	CI
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	23-10-02	CI
Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2023, has closed with 15,201,200 shares, representing 7.65% for ¥34,999.80 million.	23-10-01	CI
Alfresa unit Cell Resources Partners with Miltenyi Biotec to Advance Cell Culture Automation in Gene Cell Therapy Market	23-08-22	MT
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year Ending March 31, 2024	23-08-08	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending March 31, 2023	23-08-08	CI
Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2023.	23-07-03	CI
Alfresa Plans up to 35 Billion Yen Share Buyback; Shares Up 6%	23-05-16	MT
Alfresa Holdings Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
Alfresa Holdings Corporation Provides Commemorative Dividend Guidance for the Second Quarter 2024	23-05-15	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending March 31, 2023	23-05-15	CI
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year Ending March 31, 2024	23-05-15	CI
Alfresa Holdings Corporation announces an Equity Buyback for 21,000,000 shares, representing 10.37% for ¥35,000 million.	23-05-15	CI
Alfresa Holdings Corporation Announces Notice Regarding Change for Representative Directors	23-05-15	CI
Alfresa Holdings Corporation authorizes a Buyback Plan.	23-05-14	CI
Alfresa Holdings Corporation Revises Consolidated Earnings Guidance for the Full Year Ended March 31, 2023	23-04-28	CI
Upcoming 114 Trillion Yen Japan Budget Drives Equities; Orix to Take Stake in REIT Investment Firm for 500 Million Yen	23-03-27	MT
Alfresa Unit Receives 51 Million Yen Penalty for Breach of Antimonopoly Act	23-03-27	MT
Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	23-02-07	CI
Alfresa Holdings Corporation Provides Dividend Guidance for the Year Ending March 31, 2023	23-02-07	CI

Chart Alfresa Holdings Corporation

Duration

Period

More charts

Company Profile

Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alfresa Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,295 JPY

Average target price

2,288 JPY

Spread / Average Target

-0.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ALFRESA HOLDINGS CORPORATION	-4.24%	2.72B
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution